nav-left cat-right
cat-right

Merck Steps Further into HIV Space

Merck & Co. expanded its reach into the HIV arena by signing two licensing agreements for investigational drug candidates. One deal is with Chimerix, based in Research Triangle Park, NC, and the other is with Yamasa of Choshi, Japan. Merck is also planning to advance an internally developed HIV candidate, MK-1439, into a Phase IIb trial. “Despite the tremendous advances made over the past 20 years, there...

GE Healthcare, BGI Explore Stem Cell Genetics with...

GE Healthcare and China-based sequencing firm BGI signed a multiyear stem cell science collaboration that aims to provide new insights into the genetic variation of ethinically diverse human stem cell lines. The ultimate goal is to enable the development of relevant human stem cell assays for use in drug discovery and toxicity. Two projects will initially be undertaken. In the first BGI will carry out genome sequencing...

Source BioScience, DNAFORM to Offer Japanese Versi...

Source BioScience and DNAFORM are launching the Japanese version of Source BioScience’s GenomeCube® database and webstore. GenomeCube provides access to a portfolio of 20 million DNA clones and antibodies for research purposes. With the launch of the Japanese version, local research scientists will be able to access DNA clones representing nearly every known human and mouse gene in addition to many genes from...

Santen Nabs Japanese Co-Promotion Rights to Bayer ...

Santen Pharmaceuticals negotiated co-promotion rights to Regeneron Pharmaceuticals and Bayer HealthCare’s Eylea® (aflibercept; VEGF Trap-Eye) injection in Japan. Bayer’s Japanese subsidiary Bayer Yakuhin has already submitted a marketing application to the country’s regulatory authority for use of Eylea in the treatment of neovascular age-related macular degeneration (wet AMD). The deal with Santen means Bayer...

Biotie Regains Asia-Pacific Rights for VAP-1 Antib...

Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody program, BTT-1023. The decision also nixes Seikagaky’s option for Biotie’s VAP-1 SSAO small molecule inhibitors. Biotie had granted Seikagaku exclusive development and commercialization rights in Japan, Taiwan, Singapore, New Zealand, and Australia in April 2003, and the arrangement was built...

Toxins found in traditional Chinese medicine

A host of potential toxins, allergens and traces of endangered animals showed up in DNA sequencing tests on 15 Chinese traditional medicines, researchers said on Thursday. Such therapies have been used in China for more than 3,000 years, but have risen in popularity outside Asia in recent decades and now amount to a global industry worth hundreds of millions of dollars a year, according to the study in PLoS Genetics. Despite...
Page 2 of 1112345...10...Last »